Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats.
Treatment of diabetic rats with octreotide can inhibit early diabetic renal hypertrophy. Octreotide administration for 6 months from the day of diabetes induction inhibits renal hypertrophy and diminishes increase in urinary albumin excretion. To investigate the effect of octreotide on manifest diabetic renal changes, octreotide treatment was given for 3 weeks after an untreated diabetic period of 3 or 6 months. In addition, following 6 months of diabetes, a group of diabetic rats was treated with insulin for 3 weeks. Renal and glomerular hypertrophy, and increased urinary albumin excretion were observed in diabetic rats compared to non-diabetic control rats from 3 months and throughout the study period. Octreotide treatment did not affect body weight, food intake, blood glucose or serum fructosamine levels. We observed no effect of octreotide treatment on renal and glomerular hypertrophy or urinary albumin excretion compared to placebo-treated diabetic rats. Insulin treatment for 3 weeks after 6 months of untreated diabetes normalized blood glucose and serum fructosamine levels, and furthermore renal hypertrophy was significantly diminished compared to the placebo-treated diabetic rats. However, insulin treatment had no effect on glomerular hypertrophy or urinary albumin excretion. In conclusion, octreotide treatment for 3 weeks following an untreated diabetic period of 3 or 6 months is unable to reduce the increased renal and glomerular volume or urinary albumin excretion. However, insulin treatment for 3 weeks with induction of euglycaemia diminishes the renal hypertrophy but has no effect on glomerular volume or urinary albumin excretion.
Grønbaek
H
H
Institute of Experimental Clinical Research, Aarhus Kommunehospital, Denmark.
Nielsen
B
B
Osterby
R
R
Harris
A
A
Orskov
H
H
Flyvbjerg
A
A
D000419:Albuminuria / Q000188:drug therapy* / Q000652:urine; D000818:Animals; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002352:Carrier Proteins / Q000032:analysis / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D019270:Fructosamine; D006595:Hexosamines / Q000097:blood; D006984:Hypertrophy; D007328:Insulin / Q000627:therapeutic use*; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000187:drug effects; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007678:Kidney Glomerulus / Q000187:drug effects* / Q000473:pathology; D015282:Octreotide / Q000627:therapeutic use*; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar
D001786:Blood Glucose; D002352:Carrier Proteins; D006595:Hexosamines; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D019270:Fructosamine; D007334:Insulin-Like Growth Factor I; D015282:Octreotide